641571-13-3

Basic information

• Product Name: 3-(4-Methylimidazol-1-yl)-5-trifluoromethylbenzoic acid
• Synonyms: 3-(4-Methylimidazol-1-yl)-5-trifluoromethylbenzoic acid;3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)BENZOIC ACID;Nilotinib Impurity 14
• CAS NO: 641571-13-3
• Molecular Formula: C₁₂H₉F₃N₂O₂
• Molecular Weight: 270.21
• Product Categories: API intermediates
• Mol File: 641571-13-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 423.524 °C at 760 mmHg
• Flash Point: 209.94 °C
• Appearance: /
• Density: 1.407 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-(4-Methylimidazol-1-yl)-5-trifluoromethylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Methylimidazol-1-yl)-5-trifluoromethylbenzoic acid(641571-13-3)
• EPA Substance Registry System: 3-(4-Methylimidazol-1-yl)-5-trifluoromethylbenzoic acid(641571-13-3)

Safety Data

• Hazardous Substances Data: 641571-13-3(Hazardous Substances Data)

Usage

Uses

3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzoic Acid acts as a synthetic reagent used in the preparation and in antitumor activity of pyrrolo[2,3-d]pyrimidine derivatives against A375 human melanoma cells.

Upstream product

• 149793-69-1 3-fluoro-5-trifluoromethyl-benzonitrile 
• 822-36-6 4-methyl-1H-imidazole 
• 161622-05-5 3-fluoro-5-(trifluoromethyl)benzoic acid 
• 328-67-6 3-bromo-5-(trifluoromethyl)benzoic acid 
• 641571-12-2 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile 

Downstream Products

• 677704-46-0 3-(4-methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide 
• 851319-34-1 N-(3-nitro-4-methylphenyl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide 
• 1237750-52-5 3-(4-methyl-1H-imidazol-1-yl)-N-(4-methyl-3-(1-methyl-7-(methylthio)-2-oxo-1,2-dihydropyrimido[4,5-d]pyrimidin-3(4H)-yl)phenyl)-5-(trifluoromethyl)benzamide 
• 1318241-46-1 (E)-N-(3-(2-(4-aminothieno[3,2-d]pyrimidine-7-yl)vinyl)-4-methylphenyl)-3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)benzamide 
• 641571-11-1 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline 
• 1370335-61-7 C₁₄H₁₅F₃N₄O 
• 1261242-36-7 N-(2-((4-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)pyrimidin-2-yl)amino)ethyl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide 
• 851319-33-0 4-chloro-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid {2-methyl-5-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-benzoylamino]-phenyl}-amide 

Relevant articles and documents

AN IMPROVED PROCESS FOR 3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL) ANILINE

The present invention relates to an improved process for the preparation of 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl) aniline of Formula (I).

PROTEIN KINASE INHIBITORS

The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.

A type-ii kinase inhibitor capable of inhibiting the T315I "Gatekeeper" mutant of Bcr-Abl

The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I "gatekeeper" mutation. Here we describe a type-II T315I inhibitor 2 (GNF-7), based upon a 3,4-dihydr